title: Autologous hematopoietic cell transplantation: an update for clinicians.
abstract: High-dose chemotherapy followed by transplantation of autologous hematopoietic progenitor cells has a proven track record of safety and efficacy in hematological malignancies and select solid tumors. The near-universal use of peripheral blood stem cells as source for autografts, routine growth factor support, and antimicrobial prophylaxis post transplantation has improved the safety of this procedure. However, the advent of highly active novel therapies in the last few years warrants reappraisal of the role of autologous transplantation in the therapeutic armamentarium of malignant disorder. This review summarizes the current role of autologous transplantation for hematological malignancies, discusses modern standards for patient selection, and highlights long-term care issues of transplant survivors from an internist's perspective. Role of tumor purging in autologous transplantation, novel transplant conditioning regimens, and post-transplant therapies to prevent disease relapse are reviewed.
authors.affiliation: Division of Hematology & Oncology, Medical College of Wisconsin , Milwaukee, WI , USA.
authors.forename: Mehdi
authors.initials: M
authors.lastname: Hamadani
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D017567:Karnofsky Performance Status; D007938:Leukemia / Q000628:therapy*; D008223:Lymphoma / Q000628:therapy*; D009101:Multiple Myeloma / Q000628:therapy*; D018579:Patient Selection; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous / Q000009:adverse effects
keywords: Autologous transplantation; lymphoma; myeloma; purging; stem cell mobilization